Engineering eukaryotic protein factories.
The biopharmaceuticals market is currently outperforming the pharmaceuticals market and is now valued at US$ 48 billion with an average annual growth of 19%. Behind this success is a 100-fold increase in productivities of eukaryotic expression systems. However, the productivity per cell has remained unchanged for more than 10 years. The engineering of the ER-resident protein folding machinery is discussed together with an overview of signal transduction pathways activated by heterologous protein overexpression to increase cell specific productivities.
Schröder
Martin
M
School of Biological and Biomedical Sciences, Durham University, South Road, Durham DH1 3LE, UK. martin.schroeder@durham.ac.uk
D000818:Animals; D001702:Biopharmaceutics; D005057:Eukaryotic Cells; D006801:Humans; D015202:Protein Engineering; D017510:Protein Folding; D012441:Saccharomyces cerevisiae / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics; D020506:Untranslated Regions / Q000235:genetics / Q000502:physiology
D020506:Untranslated Regions